18 January 2022

Data from CORIST-trial to be presented at ASCO Gastrointestinal Cancers Symposium

Attachments Download report
Data with Scandion Oncology’s lead compound SCO-101 as combination therapy in patients with metastatic colorectal cancer accepted for poster presentation.

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, will have clinical data for its lead compound SCO-101 presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place on January 20-22, 2022.

Pharmacokinetic data from part 1 of the CORIST Phase II-trial in patients with metastatic colorectal cancer will be announced at a poster presentation. These data will provide details to the topline results communicated earlier documenting the unique mode of action for SCO-101 which provides a significant potentiation of the chemotherapy Irinotecan when combined with the chemotherapy regimen FOLFIRI (which includes Irinotecan).

“We are very pleased to have these data accepted for presentation at the ASCO Gastrointestinal Cancers Symposium, making it available to a large number of physicians and other stakeholders. We are excited by the data that confirms the potential of SCO-101 to significantly improve treatment options for patients”, says Bo Rode Hansen, President & CEO of Scandion.

The combination of SCO-101 and FOLFIRI resulted in a dramatically increased exposure and half-life of SN-38, the active metabolite of Irinotecan. In other words, SCO-101 has the potential to make the chemotherapy much more effective without increasing side effects for patients.

Further to these findings, part 1 of the CORIST trial has also, as previously announced, helped establish a well-tolerated dose of SCO-101 in combination with FOLFIRI. Further, the trial identified the oncogene RAS as a predictive biomarker, helping to optimize patient inclusion in the ongoing second part of the trial, which is expected to conclude in the second half of 2022.

The abstract titled “Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI” will be published at the conference website later today: https://conferences.asco.org/gi/abstracts

For further information please contact:

Mads Kronborg, Head of External Communication

Phone: +45 6051 4955

E-mail: ir@scandiononcology.com

The information was provided by the contact person above for publication on January 18, 2022, at 11.00 CET.

Scandion Oncology, the Cancer Drug Resistance Company, is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments Download report